Iressa (ZD1839)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonresectable Adrenocortical Carcinoma
Conditions
Nonresectable Adrenocortical Carcinoma
Trial Timeline
Aug 1, 2004 → Jan 1, 2007
NCT ID
NCT00215202About Iressa (ZD1839)
Iressa (ZD1839) is a phase 2 stage product being developed by AstraZeneca for Nonresectable Adrenocortical Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00215202. Target conditions include Nonresectable Adrenocortical Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00215202 | Phase 2 | Completed |